Previous 10 | Next 10 |
2023-08-07 16:04:22 ET MannKind press release ( NASDAQ: MNKD ): Q2 Non-GAAP EPS of $0.00 beats by $0.04 . Revenue of $48.61M (+157.3% Y/Y) beats by $5.66M . 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q ...
Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 2023 2Q 2023 Endocrine Business Unit net revenues of $18M; Afrezza net revenues +27% vs. 2Q 2022 2Q 2023 Income ...
2023-08-06 08:01:00 ET The second week of August promises to be an eventful one for investors as a slew of major companies is set to report quarterly results. Among the headliners, Disney ( NYSE: DIS ) is prehaps the most well-known company due to report. The schedule also incl...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today tha...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate up...
2023-07-26 07:00:40 ET Summary MannKind, a biopharmaceutical firm, has shown remarkable growth, with Q1 2023 revenue up 239% year-on-year, primarily due to higher demand for key products. Despite substantial debt and a high EV/Sales ratio, MNKD demonstrates potential with its prod...
2023-07-13 07:31:33 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty a...
2023-07-13 07:00:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “ biotech stocks to ...
2023-06-23 13:40:23 ET Summary Liquidia and MannKind are competing to secure the most significant revenue stream for their respective PAH drugs, both containing the active ingredient Treprostinil. Liquidia's stock has increased by 96% in the past year, while MannKind's stock has r...
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza ® (insulin human) Inhalation Powder) Time-in-range during waking hours remains a challenge despite advances in diabetes technology ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17%...
17-week endpoint results comparing Afrezza ® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck ...